골수암 뇌연수막 전이를 동반한 유방암 환자의 장기 생존 1예

김효정 부산대학교 병원 암연구소 2007 부산대병원학술지 Vol.- No.37

암 생쥐에서 naloxone이 testosternone으로 인한 유해감각예민도 둔화에 미치는 영향 ; 남성화군과 대조군의 비교

박제민 ; 최상헌 ; 연환지 ; 김명정 ; 김성곤 부산대학교 병원 암연구소 2002 부산대병원학술지 Vol.- No.11

호중구감소성발열 환자에서 이트라코나졸 초기 투여의 효과

최영진 부산대학교 병원 암연구소 2008 부산대병원학술지 Vol.- No.24

Background : The early diagnosis of fungal infections is difficult and persistent fever may be the only symptom. A delay in treatment, while pursuing the diagnosis, may lead to increased mortality and morbidity. The aim of this study was to evaluate defervescence and response rate of early initiation of Itraconazole in febrile neutropenic patients. Patients and methods : This was an observational study between early initiation group and historical gourp. Early initiation group defines simultaneous providing of itraconazole and broad spectrum antibiotics in neutropenic fever patients, and historical group defines providing of itraconazole in persistent fever patients in spite of 5 days of broad spectrum antibiotics. Results : A total of 88 patients were enrolled. 64 patients received itraconazole early, and 24 patients were received itraconazole conventionally. Demographic and baseline clinical characteristics were similar in both group. The defervescence rates were 85.94% vs 65.2% (p-value 0.015). The overall response rates were 67.3% vs 52.6% (p-value 0.57). Adverse events including liver dysfunction and renal dysfunction were similar both group(p-value 0.78, p-value 0.33). Conclusion : Early initiation of itraconazole has similar efficacy and toxicity to conventional treatment of itraconazole. 목적 혈액 종양 질환으로 항암 화학 요법 치료 혹은 조혈모세포이식을 시행한 환자에서 발생하는 호중구 감소성 발열의 원인이 초기에 진균 감염으로 확진 되는 비율이 2~10%로 알려져 있다. 본 연구는 혈액 종양 질환 환자에서 호중구 감소성 발열이 발생했을 때 초기 경험적 항생제와 동시에 이트라코나졸을 투여함으로써 이전의 초기 항생제 투여 후에도 5~7일 이상 발열이 지속되는 경우 이트라코나졸을 투여한 historical 군과 비교하여 효과와 안전성을 보고자 하였다. 대상과방법 부산 및 경남 지역 대학 병원에서 혈액종양질환으로 항암 치료 혹은 조혈모세포이식을 시행 받는 환자들 중 호중구<0.5 X 10^(9)/1가 최소한 7일 이상 지속될 것으로 예측되면서 호중구 감소성 발열이 있는 16세 이상의 성인 환자를 대상으로 하여 호중구성 발열 제1일에 이트라코나졸을 항생제와 같이 투여한 군과 초기 경험적 항생제를 사용하고도 호중구 감소성 발열이 5-7일 이상 지속되는 경우 1차로 이트라코나졸을 사용한 환자를 historical 군을 대상으로 하여 그 반응과 해열율을 비교하였다. 결과 Itraconazole군은 64명, historical 군은 24명이었으며 총 88명 중 남녀비율은 43명 : 45명으로 성별에 따른 차이는 없었다. 중간 나이는 itrconazole 군이 48세, historical 군이 50세 였고 두군다 기저 질환으로 AML이 가장 많았다. 해열이 된 사람은 전체 88명 중 70명 이었으며 itraconazole 군 55명 (85.94%) historical 군 15명 (62.5%) 였으며 (p=0.0152) 반응율은 itraconazole 군이 67.3 %, historical 군이 52.6 % (p-value 0.57)로 통계적 차이는 없었다. 독성으로는 간독성이 발현된 경우가 총 88명 중 31명으로 가장 많았으며 다음으로 신독성이었다. 결론 상기 연구에서 itraconazole을 호중구성 발열 환자에게 조기에 투여하는 것이 명백한 이득을 준다는 것을 밝히지는 못하였으나 혈액종양환자의 진균감염 치료에 있어 하나의 대안이 될 수 있을 것이다.

분화성 갑상선암종 환자의 수술요법 후 혈청 타이로글로불린

한군택 부산대학교 병원 암연구소 2001 부산대병원학술지 Vol.- No.9

적용범위 내의 단락의 간세포암에 대한 방사선 색전술 후 발생한 방사선 폐렴 : Radiation pneumonitis after radioembolization in tolerance degree of pulmonary shunting

우현영 부산대학교 병원 암연구소 2014 부산대병원학술지 Vol.- No.36

췌장 체미부 관선암의 췌미부-비장 절제술의 치료 효과

심문섭 부산대학교 병원 암연구소 2008 부산대병원학술지 Vol.- No.24

Purpose: Although surgical technique in pancreatic cancer has seen significant development, the prognosis of ductal adenocarcinoma of the pancreatic body and tail is dismal because of it is usually diagnosed at an advanced stage. The aim of this study was to evaluate the clinical outcomes after distal pancreatectomy with splenectomy of adenocarcinoma in the pancreatic body and tail. Patients and Methods: 8 patients with ductal adenocarcinoma of the pancreatic body and tail were operated distal pancreatectomy with splenectomy between 1997 and 2007. Data from the operative notes, pathologic reports, and postoperative data were reviewed. Results: The median age was 62 years, range 49-75 years. Curative resection (R0) was achieved in 4 patients, and microscopically radical resection (R1) was achieved in 4 patients. The median survival was 15 months, and the 1-/2-year survival was 62.5%/31.3%. Two patients had a survival exceeding 2 years (37 and 25 months). Conclusion: Selected patients with ductal adenocarcinoma of the pancreatic tail and body may be operated on with distal pancreatectomy with splenectomy and with results similar to extended curative resection. But if the tumor size were above 5.0cm, extended resection should be needed.

폐암과 암줄기세포 : Lung cancer stem cells

이민기 부산대학교 병원 암연구소 2014 부산대병원학술지 Vol.- No.36

부산대학교병원의 2007년 유방암 환자의 임상적 특성

배영태 부산대학교 병원 암연구소 2008 부산대병원학술지 Vol.- No.24

Background: In Korea the incidence of breast cancer is continuous increasing and most common cancer in cancers in women. Purposes: Purposes of the present study were to evaluate the number of the patients with breast cancers, age distribution, cancer stages, and methods of treatment of breast cancer. Methods: Author studied the clinical data of breast cancer patients who were treated in department of surgery, Pusan National University Hospital In 2007. Results: The total number of patients were 310 female patients and there was no male patient The most prevalent age was the fifth decades with youngest age of 17 years and oldest age of 86 years, and median age was 48 years. The duration of symptoms was most frequent(29.0%), between 1 to 3 month, and more than 3 years took up 3.7%. The most common sign and sympoms was painless lump (34.4%), and the most common location of the tumor was upper out quadrant (52.2%). The main preoperative diagnostic methods were Core Needle biopsy (70.1%). The breast conservation surgery were performed in 56.1% mastectomy in 31.0%. According to TNM staging system, stage Ⅱ was in 41.0%, stageⅠin 29.7%, stage 0 in 11.9%, and stage Ⅲ in 14.3%. The most common pathologic type was invasive ductal carcinoma (81.6%). The positive rate of ER was 67.5%, and PgR was 60.3%. Conclusionions: Several characteristics of breast cancer among these patients are following the patterns of Western countries, remarkably this study showed major modality of surgery was breast conservation surgery with good patient satisfaction and cosmetic results but this study was needed to understand recurrence rate, disease free survival rate etc through continuous investigations as the present study in the future.

응급의료정보센터의 병원 간 전원 기능 폐지 후 부산지역 응급실 의사들의 입장

조석주 부산대학교 병원 암연구소 2015 부산대병원학술지 Vol.- No.37

국소 진행성 두경부암의 S-1과 Cisplatin의 유도 화학요법

정주섭,최영진,설영미,송무곤,신호진,조군제 부산대학교 병원 암연구소 2008 부산대병원학술지 Vol.- No.23

Objective: This study was performed to assess the efficacy and safety profiles of the combination treatment with S-1 and Cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Design: Eligibility criteria consisted of histologically confirmed SCCHN, stage III or IV with no evidence of distant metastasis, evaluable lesions, adequate organ function, age of 20-80 years, and a performance status of 2 or less. Cisplatin was infused over 1 hour on day 1 (75 mg/m²) and S-1 was administered orally for 14 consecutive days (days 2-15). The dosages of S-1 were assigned according to the patients' body surface area (BSA): 50 mg twice a day (B5A<1.5m²),or 60 mg twice a day (B5A>1.5m²). Each course was repeated every 3 weeks. After 2 courses, tumor response was evaluated by CT scan and laryngoscopy. If the patients achieved a response (complete response: CR, or partial response: PR), they received one more course of chemotherapy before undergoing radical treatment such as radiotherapy or operation. Results: All 30 patients were assessable for toxicity, and 29 patients for response. Theoverall response was 89.7 % (CR:9, PR:17). 2 year estimated overall survival rate was 79.2 %. Adverse reactions occurred 128 times during 81 courses in the 30 cases. The most common grade 3/4 adverse event was neutropenia, which occurred in 8 patients. Non-hematological grade 3 or 4 toxicity included nausea and vomiting in 4 patients, stomatitis in 2 patients, and diarrhea in 1 patient. Conclusion: S-1 plus cisplatin combination chemotherapy is effective against locally advanced SCCHN with mild toxicity.